| 摘要 |
An antiviral preparation comprising as an active ingredient, a phorbol derivative of formula 1: wherein is R<SUB>1 </SUB>-(CH<SUB>2</SUB>)<SUB>a</SUB>X(CH<SUB>2</SUB>)<SUB>b</SUB>CH<SUB>3</SUB>, -(CH<SUB>2</SUB>)<SUB>c</SUB>X(CH<SUB>2</SUB>)<SUB>d</SUB>YCH<SUB>3</SUB>, -CO(CH<SUB>2</SUB>)<SUB>e</SUB>CH<SUB>3 </SUB>or -(CH<SUB>2</SUB>)<SUB>f</SUB>CH<SUB>3 </SUB>R<SUB>2 </SUB>is -CO(CH<SUB>2</SUB>)<SUB>n</SUB>CH<SUB>3</SUB>, R<SUB>3</SUB>, R<SUB>4 </SUB>and R<SUB>5 </SUB>are hydrogen atom, or an aliphatic or aromatic carboxylic acid residue, X and Y are O or S, and each of a-f and n is a number, and having a specific safety index S.I.=CC<SUB>50</SUB>/EC<SUB>50 </SUB>of 10 or more wherein EC<SUB>50 </SUB>means a concentration at which HIV-1 induced cytopathogenic effect (CPE) in MT-4 cell is inhibited by 50%, and CC<SUB>50 </SUB>means a concentration at which survival of MT-4 cell in a cell proliferation test is reduced by 50%. These preparations are particularly effective for human immuno-deficiency virus (HIV).
|
